REMEDIES FOR DISEASES TO BE APPLIED TO EYE

(19)

(11)

EP 1 621 199 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.01.2011 Bulletin 2011/03

(45)	Mention of the grant of the patent:
	17.11.2010 Bulletin 2010/46

(21)	Application number: 04727990.6

(22)	Date of filing: 16.04.2004

(51)

International Patent Classification (IPC):

A61K 31/56^(2006.01)
A61K 31/568^(2006.01)
A61K 9/06^(2006.01)
A61K 47/40^(2006.01)
A61P 27/02^(2006.01)
A61P 27/10^(2006.01)

A61K 31/565^(2006.01)
A61K 45/00^(2006.01)
A61K 9/08^(2006.01)
A61P 5/00^(2006.01)
A61P 27/06^(2006.01)
C07J 1/00^(2006.01)

(86)	International application number:
	PCT/JP2004/005479

(87)	International publication number:
	WO 2004/091630 (28.10.2004 Gazette 2004/44)

(54)	REMEDIES FOR DISEASES TO BE APPLIED TO EYE MITTEL ZUR BEHANLDUNG VON KRANKHEITEN ZUR AUFBRINGUNG AUF DAS AUGE REMEDES A DES AFFECTIONS, A USAGE OPHTALMIQUE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

18.04.2003 JP 2003114969
12.05.2003 JP 2003132910
19.09.2003 JP 2003329165
14.10.2003 JP 2003354135
31.03.2004 WO PCT/JP2004/004709

(43)	Date of publication of application:
	01.02.2006 Bulletin 2006/05

(60)	Divisional application:
	10177962.7
	10178007.0
	10182380.5
	10182409.2
	10182452.2

(73)	Proprietor: Advanced Medicine Research Institute
	Setagaya-ku Tokyo 158-0085 (JP)

(72)	Inventor:
	OKAMOTO, Shinseiro Setagaya-ku Tokyo 158-0085 (JP)

(74)	Representative: Hiebl, Inge Elisabeth
	Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 80539 München 80539 München (DE)

(56)

References cited: :

WO-A-94/15582
WO-A1-01/41757
JP-A- 2 009 825
JP-A- 6 511 513
JP-A- 2000 514 442
JP-A- 2003 505 345
US-A- 4 877 774
US-A- 5 521 168
US-A1- 2001 041 745

WO-A-98/03180
WO-A2-02/40032
JP-A- 6 508 362
JP-A- 7 501 081
JP-A- 2002 539 166
US-A- 4 383 992
US-A- 4 983 586
US-A- 5 624 940

XIA S. ET AL.: 'The Estrogen Receptor Is Not Essential for All Estrogen Neuroprotection: New Evidence from a New Analog' NEUROBIOLOGY OF DISEASE vol. 9, 2002, pages 282 - 293, XP002980079
SULLIVAN D.A. ET AL.: 'Androgen Stimulation of Lacrimal Gland Function in Mouse Models of Sjögren's Syndrome' J. STEROID BIOCHEM. MOLEC. BIOL. vol. 60, no. 3-4, 1997, pages 237 - 245, XP002980080

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).